Objective. Misuse and abuse of prescription opioids remains a major healthcare concern despite considerable efforts to increase public awareness. Abuse-deterrent formulations of prescription opioids are designed to reduce intentional misuse, abuse, and prescription opioid-related death. A novel extended-release (ER) formulation of morphine (Morphine ARER; MorphaBond TM ) resists physical manipulation and retains the drug's ER characteristics, even if attempts are made to manipulate the formulation.
Introduction
The misuse and abuse of opioid medications continues to be a major healthcare concern despite efforts to increase public awareness and reduce prescription drug diversion for nonmedical use [1] . In the United States, there are approximately 12 million annual nonmedical opioid users and more than 16,600 fatal overdoses involving prescription opioids each year [2, 3] . Opioids are often obtained from legitimate prescriptions, but are diverted for recreational drug abuse [4] . Approximately 70% of recreational users report that they obtained opioids from friends and/or family [1] .
To address the growing opioid abuse problem, prescription drug monitoring programs and policies have been established in most states to track and regulate controlled substances [4, 5] . These programs fulfill part of the Prescription Drug Abuse Prevention Plan from the Office of National Drug Control Policy, but they do not directly deter opioid abuse [6] .
Abuse-deterrent formulations combat opioid abuse by individuals seeking to use opioids for nonmedical use [7] . The introduction of an abuse-deterrent formulation of extended-release (ER) oxycodone (OxyContin TM , Purdue Pharma LP, Stamford, CT) appears to have significantly decreased its selection as the primary opioid of choice for abuse; the abuse of ER oxycodone decreased from 35.6% to 12.8% of survey respondents in just 21 months after its release (P < 0.001) [8] . Significant decreases in ER oxycodone abuse by routes of administration that require manipulation were also reported; intranasal and intravenous abuse decreased from 53% to 25% and 36% to 16%, respectively [9] . A concern, however, is that as more abuse-deterrent formulations of ER opioids are approved, abusers may choose to use other non-abuse-deterrent ER formulations, such as generic ER morphine, or potentially switch to non-abuse-deterrent immediate-release formulations of these medications [8] [9] [10] .
Prescription opioid abusers often initiate abuse by ingesting opioids orally, but a subset move on to manipulate formulations for nonprescribed routes of administration, including intranasal, intravenous, and smoking routes, which are associated with an increase in the opioid's bioavailability and a greater abuse liability [11] [12] [13] . The intranasal route of administration is widely used by abusers because of the ease in preparation (simply crushing the tablet into a fine powder) and the lack of first-pass metabolism, which ensures a faster increase in opioid plasma levels [9, 11, 14] . A quick increase in opioid plasma levels results in a more rapid entry into the brain, which increases the drug liking and reinforcement properties of the drug [11] .
Abuse-deterrent formulations of opioids should target methods of manipulation and routes of administration often used for opioid abuse. A variety of methods are under investigation to decrease the overall abuse potential of opioids, including the incorporation of opioid antagonists or aversive agents that are released only after manipulation, prodrugs that are only activated via the intended route of administration, and the incorporation of physiochemical barriers that are added to increase the hurdles in preparing the formulation for misuse and abuse [11] [12] [13] .
Morphine is commonly abused via the oral, intranasal, and intravenous routes [11, 15] . A novel abuse-deterrent formulation of oral ER morphine sulfate tablets (Morphine ARER, MorphaBond, Inspirion Delivery Technologies, LLC, Valley Cottage, NY) incorporates proprietary SentryBond abuse-deterrent technology, making the tablets more difficult for individuals to adulterate them for misuse and abuse. Morphine ARER tablets resist physical manipulation with household tools, retain ER characteristics despite attempts at physical and chemical manipulation, and form a nonsyringeable material in liquid environments, which resists passage through a needle [16] [17] [18] . These unique properties create barriers to commonly used methods of manipulation and routes of administration, thus achieving abuse deterrence without the potential risks of using opioid antagonists or aversive agents.
In accordance with the US Food and Drug Administration (FDA) Guidance on Abuse-Deterrent Opioids [19] , an intranasal drug liking study was performed to evaluate the intranasal abuse potential of Morphine ARER relative to the reference-listed drug in nondependent recreational opioid users.
Methods

Participants
This study included male and female healthy volunteers between the ages of 18 and 55 years. Subjects were eligible to participate if they were not physically dependent on opioids but had used opioids for nontherapeutic purposes on at least 10 occasions within the last year and at least once in the 12 weeks prior to screening. Additionally, subjects needed to have at least three experiences with insufflating drugs within the last year. Subjects were excluded if they had participated in, were currently participating in, or were seeking treatment for substance-related disorders, or if they had a history or presence of drug or alcohol dependence, excluding nicotine and caffeine. In addition, with the exception of tetrahydrocannabinol, subjects were excluded if they had a positive urine drug screen at the screening visit or during the qualification period. Subjects were also excluded if they had a history or presence of any clinically significant conditions or illnesses such as cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease. Finally, subjects were excluded for any condition that, in the opinion of the Investigator, would have jeopardized the safety of the subject or the validity of the results, and excluded for any condition in which an opioid was contraindicated. Subjects provided written informed consent to participate in the study.
Study Design and Treatment
This randomized, double-blind, double-dummy, placebo-controlled, single-dose, four-way crossover, single-center study was comprised of a screening period, a qualification period, a study drug treatment period, and a follow-up period (Figure 1 ). The qualification period consisted of a three-night inpatient, double-blind qualifying session during which a naloxone challenge test and drug discrimination test were administered. During the naloxone challenge test, an initial dose of 0.2 mg of naloxone hydrochloride was administered by intravenous bolus and the subject was observed for signs or symptoms of withdrawal using the Clinical Opiate Withdrawal Scale. This scale contains 11 items for which the investigator rated signs and symptoms of opioid withdrawal, including pulse rate, gastrointestinal upset, sweating, tremor, restlessness, yawning, pupil size, anxiety or irritability, bone or joint aches, goosefleshed skin, and runny nose or tearing. If no evidence of withdrawal occurred in the subject within 30 seconds, 0.6 mg of naloxone hydrochloride was then administered and the subject was observed for an additional five minutes.
Subjects who did not experience symptoms of withdrawal proceeded to the drug discrimination test. In a two-way crossover, 1:1 ratio format using a computergenerated randomization scheme, subjects received a single, intranasal dose each of morphine sulfate immediate release (30 mg crushed tablet) and placebo (crushed placebo tablet). Crushed placebo tablet was added to the crushed morphine sulfate tablet to ensure that subjects could insufflate the volume required for the treatment period. Each dose was separated by at least 24 hours. The investigator assessed whether subjects were able to distinguish morphine from placebo based on their responses on a drug liking bipolar visual analog scale (VAS). If subjects could distinguish the morphine from placebo and if they were able to tolerate intranasal administration of morphine, subjects were eligible to continue in the trial.
Subjects who entered the double-blind treatment period were randomized to one of four treatment sequences based on a Williams pair design [20] . During the treatment period, subjects received four different treatments in the order specified by treatment sequence in a fourway crossover double-dummy design separated by a minimum seven-day washout period. Each treatment period consisted of a two-night in-center stay for dosing. Subjects received the following treatments: crushed intranasal placebo plus intact oral placebo (referred to as placebo), crushed intranasal ER morphine (ER morphine, MS Contin TM , Purdue Pharma, LP, Stamford, CT) 60 mg (with crushed placebo tablet added for volume) plus intact oral placebo (referred to as crushed intranasal ER morphine), crushed intranasal Morphine ARER 60 mg plus intact oral placebo (referred to as crushed intranasal Morphine ARER), and crushed intranasal placebo plus intact oral Morphine ARER 60 mg (referred to as intact oral Morphine ARER). To ensure blinding, subjects were dosed individually in a private room, their dose was prepared behind a privacy screen by Figure 1 Subject disposition through all treatment phases. ER morphine ¼ extended-release morphine sulfate tablets; Morphine ARER ¼ abuse-deterrent formulation of oral ER morphine sulfate tablets. unblinded pharmacists, and the doses were prepared in the same manner for all four treatments (three lines of crushed drug for inhalation plus oral tablets). All other staff remained blinded throughout the conduct of the study. All randomization codes were generated before the start of the study by a statistician who was not involved with the conduct of the study. After completion of the treatment period, subjects returned in seven to 10 days as outpatients to complete a follow-up visit.
The study was conducted between October 22, 2012, and January 3, 2013, and was conducted in accordance with the Good Clinical Practice Guideline (Title 21 of the Code of Federal Regulations Parts 50, 56, and 312) [21] , the International Conference on Harmonisation (ICH) [22] , The Declaration of Helsinki [23] , and all applicable federal and local regulation and institutional review boards. All subjects provided written informed consent to participate in the study.
Assessments
Drug Liking Bipolar Visual Analog Scale
The primary endpoint was the mean maximum effect (E max ) for drug liking between crushed intranasal Morphine ARER and crushed intranasal ER morphine. Secondary comparisons for the primary endpoint included E max for intact oral Morphine ARER compared with crushed intranasal ER morphine and crushed intranasal Morphine ARER. Subjects completed a bipolar drug liking VAS at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose. Subjects responded to the question "Do you like the drug effect you are feeling now?" by marking a single vertical line on the VAS where appropriate. The response to the question was scored using a 0 to 100 mm bipolar VAS anchored on the left with "strong disliking" (score of 0), "neither like nor dislike" (score of 50) in the middle, and anchored on the right with "strong liking" (score of 100). The overall mean and median as well as individual subjects' percent reduction in E max were calculated per the recommendation in the Guidance as:
where c i , t i , and p i are the E max values for the control (crushed intranasal ER morphine), test (crushed intranasal Morphine ARER), and placebo, respectively; from the ith subject and N is the sample size.
Drug Effects Questionnaire
The eight-item unipolar drug effects questionnaire (DEQ) was used to assess the drug effects noted by the subject. Questions included: "Do you feel any drug effects?"; "Does the drug have good effects?"; "Does the drug have any bad effects?"; "How high are you now?"; "Does the drug make you feel sick?"; "Do you have any nausea?"; "Does the drug make you sleepy?"; and "Does the drug make you dizzy?" Subjects completed the DEQ at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose. The question regarding nausea was solicited within one hour predose. For each DEQ question, subjects responded by marking a vertical line on a 0 to 100 mm unipolar VAS anchored on the left by "none" (score of 0) and on the right by "extremely" (score of 100).
Overall Drug Liking Visual Analog Scale
Subjects' global perceptions of drug liking were assessed using a 0 to 100 mm bipolar VAS scale at 12 and 24 hours postdose. Subjects responded to the statement "Overall, my liking for this drug is:" by marking a single vertical line on the VAS scaled the same way as the drug liking VAS. The VAS was anchored on the left with "strong disliking" (score of 0), "neither like nor dislike" (score of 50) in the middle, and anchored on the right with "strong liking" (score of 100).
Take Drug Again Assessment Visual Analog Scale
The "Take Drug Again Assessment" VAS was used to assess a subject's desire to use the drug again. This scale was completed by subjects at 12 and 24 hours postdose. Subjects responded to the question "Would you want to take the drug you just received again, if given the opportunity?" by marking a vertical line on a 0 to 100 mm bipolar VAS scale anchored on the left with "definitely would not" (score of 0), "do not care" (score of 50) in the middle, and anchored on the right with "definitely would" (score of 100).
Addiction Research Center Inventory/Morphine Benzedrine Group Subscale
The Addiction Research Center Inventory/Morphine Benzedrine Group (ARCI/MBG) subscale was used to assess euphoria and positive mood. Subjects completed the ARCI/MBG subscale within one hour predose and postdose at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours. The ARCI/MBG subscale consists of 16 true/ false statements; each question is scored on a twopoint scale (0 and 1), where 0 ¼ false and 1 ¼ true. The total score is calculated by adding the individual scores with a possible total score of 16. A higher score indicates greater euphoria and positive mood.
Safety Assessments
Adverse events (AEs) were coded into system organ class and preferred terms using the Medical Dictionary for Regulatory Activities version 15.0. AEs were assessed for intensity and relation to the study drug. Complete physical examinations were performed at screening and the follow-up visits. Vital sign and pulse oximetry tests were performed at screening, qualification, treatment, and follow-up visits. Twelve-lead electrocardiography was performed at screening, qualification, and at follow-up. During the dosing phase of the treatment period, subjects were monitored with continuous telemetry from predose until eight hours postdose. Subjects provided samples for laboratory testing at screening, qualification, and follow-up.
Statistical Analysis
Assuming an approximate dropout rate of 30% between the qualification and treatment period, 42 subjects were to be enrolled to randomize 30 subjects. Assuming an additional 20% dropout from the treatment period, it was estimated that 24 subjects would complete the study. With 24 subjects, this study was powered to detect a mean difference between treatments of 0.85 relative effect size (mean to standard deviation ratio) with 80% power, assuming a two-sided a-level of 0.05. These calculations were made using SAS Proc Power (SAS Institute Inc, Cary, NC, USA) with paired means test of differences and a correlation of 0.
Unless otherwise specified, all significance testing was two-tailed using an a level of 0.05. Tests were declared statistically significant if the calculated a was 0.05 or less. The primary endpoint, E max for drug liking, measured as area under the drug liking curve from zero to one hour [AUE 0-1 ] and zero to two hours [AUE 0-2 ], was tested at an a level of 0.05 for the comparison between crushed intranasal ER morphine and crushed intranasal Morphine ARER. The comparisons for crushed intranasal ER morphine vs crushed intranasal Morphine ARER for AUE 0-1 and AUE 0-2 for drug liking were adjusted for multiplicity using the Benjamini-Hochberg method, setting the number of comparisons (m) equal to three (i.e., adjusting for comparisons for AUE 0-1 and AUE 0-2 and the previous comparison for E max ). All endpoints reported were prespecified in the statistical analysis plan.
Results
Subjects
A total of 48 subjects entered and passed the naloxone challenge test (Figure 1 ). Of these, 27 subjects passed the drug discrimination test and entered the treatment phase. Twenty-five subjects completed the treatment phase. Two subjects were withdrawn from the study during the treatment period due to a positive urine drug screen on admission to the clinic (1 subject tested positive for benzodiazepines and another subject tested positive for opioids).
Subjects in this study had a mean age of 25.4 years, and the majority (85.2%) were white males ( Table 1) . Most of the subjects were alcohol (88.9%) and tobacco (74.1%) users. In accordance with the inclusion criteria for the study, all subjects had recreationally used opioids in the past 12 weeks, with a mean number of times of 12.1 for males and 9.0 times for females.
Pharmacodynamics Assessments
Drug Liking
There was a 40% reduction in placebo-adjusted mean maximum drug liking (E max VAS scores) for crushed intranasal Morphine ARER compared with crushed intranasal ER morphine (71.13 mm vs 84.79 mm, P < 0.0001) (Figure 2 ). There was no significant difference in E max when comparing crushed intranasal Morphine ARER with intact oral Morphine ARER (71.13 mm vs 67.03 mm, P ¼ not significant). Mean drug liking was higher for crushed intranasal ER morphine relative to crushed intranasal Morphine ARER at each time point ( Figure 3 ). As expected, the majority of the drug liking reduced to placebo levels by 12 hours after administration. There were significant reductions in early drug liking, from AUE 0-1 and AUE 0-2 , when comparing crushed intranasal Morphine ARER with crushed intranasal ER morphine (6.15 hÁmm vs 15.75 hÁmm, P < 0.0001, and 19.84 hÁmm vs 44.55 hÁmm, P < 0.0001, respectively) ( Figure 4 ). There was no significant difference in early drug liking, from AUE 0-1 and AUE 0-2 , when comparing crushed intranasal Morphine ARER with intact oral Morphine ARER. Compared with crushed intranasal ER morphine, 68% of patients had a reduction in AUE 0-1 and 80% of patients had a reduction in AUE 0-2 with crushed intranasal Morphine ARER.
When comparing individual subjects' placebo-adjusted E max scores for crushed intranasal Morphine ARER with crushed intranasal ER morphine, most subjects (76%) experienced at least some reduction in drug liking ( Figure 5 ). This trend continued, with 56% of subjects experiencing at least a 30% reduction and nearly half of subjects (48%) experiencing at least a 50% reduction in drug liking. No sequence effects were observed in the study supporting maintenance of the blinding.
Secondary Endpoints
Responses to the DEQ showed similar trends in reductions in positive effects (Table 2) . When comparing crushed intranasal Morphine ARER and crushed intranasal ER morphine, there were significant reductions in E max in any effects (P ¼ 0.0003), good effects (P ¼ 0.0004), and drug high (P ¼ 0.0001). Results for the negative subjective endpoints (bad effects, sick, nausea, and dizzy) were not entirely consistent across treatments, suggesting that the reduction in drug liking for Morphine ARER was driven by decreased positive effects. For both positive and negative effects, there was no significant difference in responses to the DEQ when comparing crushed intranasal Morphine ARER and intact oral Morphine ARER.
Overall drug liking and the desire to take the drug again were both significantly reduced when comparing Morphine ARER and ER morphine (P ¼ 0.007 and P ¼ 0.0341, respectively). There was no significant difference in overall drug liking or the desire to take the drug again when comparing crushed intranasal Morphine ARER and intact oral Morphine ARER.
ARCI/MBG scores were lower for crushed intranasal Morphine ARER compared with crushed intranasal ER morphine (8.48 vs 10.56, P ¼ 0.0511), indicating a lower euphoria and positive mood. ARCI/MBG scores were significantly lower for intact oral Morphine ARER compared with crushed intranasal ER morphine (6.60 vs 10.56, P ¼ 0.0003).
Safety
All treatments were well tolerated by subjects in this study, with all AEs being mild in intensity and typical of opioid-related AEs or opioids associated with intranasal administration (Table 3 ). The most frequently occurring AEs included nasal congestion, rhinorrhea, and epistaxis, all of which are associated with intranasal administration of a drug. Nausea, vomiting, and generalized pruritus, which are all common opioid-related AEs, were the only other AEs that occurred in more than 10% of subjects.
No deaths or serious AEs occurred during the study. No subject discontinued the study prematurely because of an AE during the qualification and treatment periods. No changes in laboratory results prompted an AE, and no clinically important changes in vital signs were observed.
Discussion
The "FDA Guidance on Abuse-Deterrent OpioidsEvaluation and Labeling" recommends the evaluation of abuse-deterrent formulations of opioids in human abuse liability studies, with particular emphasis on investigating the abuse liability in the most common routes of abuse [19] . This study investigated the intranasal abuse potential of Morphine ARER, a route of administration commonly reported by abusers [11, 15] . Here the abuse potentials of crushed intranasal Morphine ARER and crushed intranasal ER morphine, as well as intact oral Morphine ARER, were evaluated. The significant reduction in drug liking for Morphine ARER relative to ER morphine suggests that Morphine ARER has a lower abuse potential via the intranasal route of administration. The majority of subjects experienced a reduction in drug liking for Morphine ARER compared with ER morphine, and nearly half the subjects experienced at least a 50% Figure 4 Early mean drug liking area under the drug effect curve (AUE) for crushed intranasal Morphine ARER, crushed intranasal ER morphine, and intact oral Morphine ARER (A) over the first hour (AUE 0-1 ) and (B) over the first two hours (AUE 0-2 ) after snorting. Mean percent reduction calculations based on ((c i -
. ., N, where c i , t i , and p i are the E max values for the control (crushed intranasal ER morphine), test (crushed intranasal Morphine ARER), and placebo, respectively, from the ith participant, and N is the sample size. ER morphine ¼ extended-release morphine sulfate tablets; Morphine ARER ¼ abuse-deterrent formulation of oral ER morphine sulfate tablets; NS ¼ not significant; VAS ¼ visual analog scale.
Figure 5
Individual subjects' percent reduction in drug liking for crushed Morphine ARER vs ER morphine after intranasal administration. The percent reduction in drug liking was calculated based on (c i -t i )/(c i -p i ) Â 100%, i ¼ 1, 2, . . ., N, where c i , t i , and p i are the E max values for the control (crushed intranasal ER morphine), test (crushed intranasal Morphine ARER), and placebo, respectively, from the ith participant, and N is the sample size. Hashed lines represent 48% of subjects who experienced at least a 50% reduction in drug liking. ER morphine ¼ extended-release morphine sulfate tablets; Morphine ARER ¼ abuse-deterrent formulation of oral ER morphine sulfate tablets.
Intranasal Liking of Abuse-Deterrent ER Morphine reduction in drug liking. These results were consistent with secondary endpoints. There was a significantly lower desire by subjects to use Morphine ARER again compared with ER morphine; subjects reported decreased good effects, drug high, willingness to take the drug again, and overall drug liking for Morphine ARER. Morphine ARER was well tolerated; other than typical AEs associated with intranasal administration (nasal congestion, rhinorrhea, and epistaxis), the AEs experienced by study participants taking Morphine ARER either orally or intranasally were consistent with the wellestablished safety profile of opioid-containing medications.
The reduced early drug liking of Morphine ARER as reported by subjects during the first two hours is an important finding in the drug's ability to deter abusers who are looking for a quick high. Abusers prefer drugs with a rapid onset of effects, and this quick "high" increases the abuse liability of the drug [11] . Reduced early drug liking takes away any immediate benefit from abusing morphine intranasally. Thus, these data suggest a lower abuse potential for Morphine ARER compared with ER morphine, particularly in the first two hours.
When evaluating the pharmacodynamics of prescription opioids, an early spike in drug liking for manipulated tablets relative to intact tablets is indicative of "dosedumping," or a rapid delivery of the opioid to the brain [11, 13] . In this study, subjects were required to insufflate three additional lines of placebo filler powdered after insufflating one line of crushed intranasal ER morphine to maintain the blind and prevent any potential sequence effect. Even though this aggressive blinding approach may have promoted gastrointestinal absorption (vs rapid intranasal absorption) in the positive control arm, administration of crushed ER morphine was associated with a rapid and large increase in mean maximum drug liking. Mean maximum drug liking for crushed intranasal ER morphine was significantly higher than oral intact Morphine ARER (84.79 mm vs 67.03 mm, P < .0001) (Figure 2 ), which is bioequivalent to oral intact ER morphine. This finding is supportive of the epidemiologic data that suggest experienced opioid abusers migrate from oral to intranasal and intravenous administration to achieve a greater high. Conversely, despite physical manipulation and intranasal administration, Morphine ARER was not associated with a comparable increase. Furthermore, the drug liking over time curves between crushed intranasal Morphine ARER and intact oral Morphine ARER were similar (see Figure  3 ), suggesting that physical manipulation does not substantially alter the intended ER characteristics of the tablets. These observations are consistent with in vitro studies of Morphine ARER showing a lack of "dosedumping" when tablets are manipulated with various household tools or extracted in a variety of household or laboratory solvents [16] [17] [18] .
Morphine ARER uses a physiochemical approach to deter abuse and is demonstrated to be resistant to physical manipulation with household tools [17] , resistant to chemical extraction with household solvents [16] , and impossible to syringe when manipulated even through small gauge (large bore) needles [18] . [12] . Finally, a potential limitation of all abuse-deterrent formulations, including those that rely upon physiochemical barriers to abuse, is that the addition of aversive agents, opioid antagonists, or other abuse-deterrent excipients often increases the size of the tablets relative to the nonabuse-deterrent formulations. In the end, the unique abuse-deterrent profiles of different formulations suggests that a prescriber's selection of an abuse-deterrent formulation should be based on each patient's unique situation, evaluating the potential for abuse by the patient themselves as well as by friends and family members with access to the patient's medication.
Challenges that are commonly associated with human abuse potential studies include self-reported subjective effects and the variability that goes with this subjectivity, as well as the choice of subject population having an effect on subjectivity [24] . Another potential weakness of data derived from human abuse potential trials is evaluating whether these data will translate to larger populations. In this study, abuse potential was assessed in a population of experienced recreational drug users, thus it is unclear whether these results will translate to other populations. In addition, these results are specific to intranasal administration; therefore, the abuse potential of Morphine ARER via other routes of administration is unknown. It is clear, however, that abuse of Morphine ARER via the oral route of administration, including ingesting higher doses than prescribed, is still possible. Thus, even though abuse-deterrent products have been shown to have less potential for abuse in human abuse potential studies, it remains important for healthcare providers to implement universal precautions and maintain judicious opioid prescribing habits. Finally, evaluations of epidemiologic data on misuse and abuse will be necessary to confirm abuse resistance in the general population.
Conclusions
The findings reported herein show that when Morphine ARER was crushed and administered intranasally and when it was taken as an intact tablet, subjects reported significantly less drug liking for Morphine ARER relative to ER morphine. This suggests that Morphine ARER has a lower abuse potential via the intranasal route when compared with ER morphine.
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